Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
Authors:
Open Access
- 29 July 2011
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 26 (2) , 356-358
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease ProgressionJournal of Clinical Oncology, 2011
- Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5qLeukemia, 2010
- Persistent Malignant Stem Cells in del(5q) Myelodysplasia in RemissionNew England Journal of Medicine, 2010
- Telomere shortening and chromosomal instability in myelodysplastic syndromesGenes, Chromosomes and Cancer, 2009
- Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q DeletionNew England Journal of Medicine, 2006
- Sex-specific telomere length profiles and age-dependent erosion dynamics of individual chromosome arms in humansCytogenetic and Genome Research, 2006
- Telomere length in myelodysplastic syndromesAmerican Journal of Hematology, 1997